Releasing the immune brakes
Your immune system can recognise and kill cancer cells — but it has built-in brakes, called checkpoints, that normally stop T cells from attacking the body's own tissue. Many tumors survive by pressing those brakes, displaying signals that tell an approaching T cell to stand down. An immune checkpoint inhibitor is a monoclonal antibody that blocks that off-switch. It does not attack the tumor directly; it releases the patient's own T cells to do the killing. This is why it is a form of biologic therapy rather than a poison.
The two best-known brakes are CTLA-4 and the PD-1/PD-L1 pair. Antibodies such as pembrolizumab block PD-1, peeling the tumor's protective signal off the T cell. The results can be remarkable: in some cancers a fraction of patients achieve durable, years-long remissions that classical chemotherapy never delivered. Honesty matters here, though — checkpoint inhibitors help only some patients with some cancers, and predicting who responds is still imperfect.
The other direction: turning the immune system down
The same field gives us drugs that do the opposite. An immunosuppressant dampens immune activity. We need this when the immune system is the problem: after an organ transplant, where T cells would otherwise reject the new organ, and in autoimmune diseases, where the body attacks itself. These are immunomodulators tuned toward 'quieter', the mirror image of checkpoint inhibitors.
- Calcineurin inhibitors (ciclosporin, tacrolimus) block a signal T cells need to switch on — the backbone of transplant regimens.
- Antiproliferatives (azathioprine, mycophenolate) — antimetabolite-style drugs that stop immune cells from multiplying.
- [[glucocorticoid|Glucocorticoids]] (prednisolone) — broad, fast anti-inflammatory dampers used for flares and rejection.
- Biologic immunosuppressants (monoclonal antibodies) that neutralise specific immune messengers like TNF.
Their shared risk is the flip side of their benefit: a turned-down immune system fights infection and surveils for new cancers less well. Patients on long-term immunosuppression face more infections and a higher risk of certain malignancies — a sober reminder that every adverse reaction here flows straight from the intended mechanism.
One dial, two directions
Immunopharmacology: the same dial, turned two ways
<-- SUPPRESS UNLEASH -->
immunosuppressants checkpoint inhibitors
(calcineurin inhib., (anti-PD-1, anti-CTLA-4)
steroids, anti-TNF)
GOAL: calm rejection / GOAL: let T cells
autoimmunity attack the cancer
RISK: infection, RISK: autoimmune-like
secondary cancer organ inflammation
Same biology, opposite goals -- and the toxicity of each is
just the other one's intended effect happening by accident.